225 Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.
Machaba Michael SathekgeFrank BruchertseiferMariza VorsterIsmaheel O LawalKgomotso MokoalaJanet ReedLetjie MaseremuleHonest NdlovuKhanyi HlongwaAlex MaesAlfred MorgensternChristophe Van de WielePublished in: European journal of nuclear medicine and molecular imaging (2023)
Ac-PSMA-617 as a therapeutic agent for mHSPC administered either as monotherapy or administered concomitant with ADT are of interest.